Compare Enveric Biosciences Inc (ENVB) vs Kroger Co (KR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Kroger Co — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Kroger Co trades at $61.28 (market cap $34.99B). The key difference: Kroger Co is far larger — about 5230.2× Enveric Biosciences Inc's market cap, and Kroger Co pays a 2.63% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Kroger Co for 108 Days on average.
| ENVB | KR | |
|---|---|---|
Market Cap | $6.69M | $34.99B |
Volume | 41,141 | 8,938,607 |
Sector | Health | Consumer Staples |
52-Week High | $10.80 | $75.60 |
52-Week Low | $1.27 | $55.53 |
Typical Hold Time | 14 Days | 108 Days |
Enterprise Value | -$1.60M | $56.41B |
Dividend Yield | — | 2.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Kroger (KR) trades at $61.41, up 5.14% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with $147.12B in revenue, though net margins remain thin at 0.73%. Recent earnings show mixed results with Q2 2026 beating expectations but Q1 2026 missing. The company maintains positive cash flow generation and continues dividend payments while facing competitive pressures in the grocery sector.
Kroger presents a balanced investment case with attractive valuation metrics (P/S 0.25) and analyst consensus pointing to 15% upside to $70.62 target. However, risks include integration challenges from acquisitions, margin pressure from price competition, and softer 2026 sales guidance. The stock offers value characteristics with dividend yield support amid ongoing digital transformation efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →
